Ulteriori informazioni
Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
Sommario
An overview of sleep physiology and sleep regulation.- Neuronal networks regulating sleep and arousal: effect of drugs.- Classification of sleep disorders.- Development of new therapeutical agents for treatment of insomnia and other sleep disorders.- Low dose doxepin for insomnia.- Lorediplon: a new GABAa modulator drug for treatment of insomnia.- Zolpidem sublingual formulations.- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia.- Orexin/hypocretin antagonists in insomnia: from bench to clinic.- Modafinil and armodafinil.- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy.- Cell therapy to treat narcolepsy.- Tasimelteon.- The past, present and future of drug development and treatment in sleep disorders.
Riassunto
Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
Testo aggiuntivo
“This book explores major breakthroughs in the drug treatment of sleep disorders. … The intended audience is scientists, clinicians, and drug developers. … With its specific aim of providing an extensive update on drug treatment for sleep disorders, this book is helpful contribution to sleep medicine.” (M. Isabel L. Crisostomo, Doody’s Book Reviews, July, 2015)
Relazione
"This book explores major breakthroughs in the drug treatment of sleep disorders. ... The intended audience is scientists, clinicians, and drug developers. ... With its specific aim of providing an extensive update on drug treatment for sleep disorders, this book is helpful contribution to sleep medicine." (M. Isabel L. Crisostomo, Doody's Book Reviews, July, 2015)
